LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

Home・Stock List・Prothena Corp PLC

Prothena Corp PLC

Closed

Sector Healthcare

20.68 -3.18

Buy Sell

Overview

Share price change

24h

Current

Min

20.61

Max

21.72

Key metrics
By Trading Economics
Income	-55M
Sales	-85M 316K
EPS	-1.26
Profit margin	-1,358.422
EBITDA	-66M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+250.66 upside

Dividends
By Dow Jones
Next Earnings	1 Aug 2024

Market Stats
By TradingEconomics
Market Cap	1.1B
Previous open	23.86
Previous close	20.68

News Sentiment

By Acuity

50%

155 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

20.26 / 22.74 Support & Resistance

Prothena Corp PLC Chart

Related News

13 May 2024, 23:35 UTC

Earnings

Thai Beverage: 1H Net Profit Weighed Down by Fall in Net Profit From Associated Companies >Y92.SG

13 May 2024, 23:34 UTC

Earnings

Thai Beverage 1H Net Profit Fell 4.9% to THB16.92B >Y92.SG

13 May 2024, 23:32 UTC

Earnings

Thai Beverage: 1H Net Profit Weighed Down Due to Lower Contributions From Associated Companies >Y92.SG

13 May 2024, 23:31 UTC

Earnings

Thai Beverage 2Q Net THB6.99B Vs. Net THB7.36B >Y92.SG

13 May 2024, 23:30 UTC

Earnings

Thai Beverage 2Q Rev THB71.63B Vs. THB67.40B >Y92.SG

13 May 2024, 23:30 UTC

Earnings

Thai Beverage 1H Rev THB147.74B Vs. THB148.30B >Y92.SG

13 May 2024, 23:30 UTC

Earnings

Thai Beverage 1H Net THB15.22B Vs. Net THB16.12B >Y92.SG

13 May 2024, 23:28 UTC

Market Talk

Earnings

Aussie Bank Margins Stabilize, Revenue Outlook Weak -- Market Talk

13 May 2024, 23:19 UTC

Market Talk

Acquisitions, Mergers, Takeovers

BHP Expected to Firm Offer for Anglo American. But Will It Be Enough? -- Market Talk

13 May 2024, 23:06 UTC

Market Talk

Global Equities Roundup: Market Talk

13 May 2024, 23:06 UTC

Market Talk

Former RBA Board Member Says Govt Rebates a 'Trick' -- Market Talk

13 May 2024, 22:58 UTC

Earnings

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW5.507T Vs KRW5.342T

13 May 2024, 22:58 UTC

Earnings

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW897.06B Vs Op KRW832.35B

13 May 2024, 22:58 UTC

Earnings

Table: Samsung Fire & Marine 1Q Consolidated Net KRW701.95B Vs KRW612.37B

13 May 2024, 22:58 UTC

Earnings

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW701.95B Vs KRW612.37B

13 May 2024, 22:44 UTC

Market Talk

Fletcher's Leverage to Weigh on Stock Valuation -- Market Talk

13 May 2024, 22:40 UTC

Market Talk

Ballooning Australian Budget Deficits to Work Against RBA Goals -- Market Talk

13 May 2024, 22:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 May 2024, 22:32 UTC

Market Talk

Tension Between RBA and Govt Is Likely Over Forecasts -- Market Talk

13 May 2024, 21:22 UTC

Peer Comparison

Price change

Prothena Corp PLC Forecast

Price Target

By TipRanks

250.66% upside

12 Months Forecast

Average 74.83 USD 250.66%

High 94 USD

Low 28 USD

Based on 6 Wall Street analysts offering 12 month price targets forProthena Corp PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Prothena Corp PLC - Dist in the past 3 months.

Technical Score

By Trading Central

20.26 / 22.74Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

155 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

EBITDA

Operating profit

About Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.